Investment Rating - The report maintains a BUY rating for Microsoft, indicating a potential return of over 15% over the next 12 months [19]. Core Insights - Microsoft reported 2QFY26 results with revenue of US$81.3 billion, reflecting a 16.7% year-over-year growth, which is 1.5% better than both the forecast and Bloomberg consensus estimates [1]. - Operating income increased by 20.9% year-over-year to US$38.3 billion, exceeding forecasts, driven by strong performance in the Productivity and Business Processes (PBP) and Intelligent Cloud (IC) segments [1]. - The target price has been revised down by 3% to US$614.6, translating into a price-to-earnings ratio of 35x for FY26E and 31x for FY27E [1][2]. Financial Performance - Revenue growth in the Intelligent Cloud segment was 28.8% year-over-year, contributing US$32.9 billion, which accounted for 40.5% of total revenue [7]. - Azure and other cloud services revenue grew by 39% year-over-year, aligning with consensus expectations [7]. - The Productivity and Business Processes segment generated US$34.1 billion in revenue, up 15.9% year-over-year, representing 42.0% of total revenue [7]. Capital Expenditure and Outlook - Capital expenditures, including financial leases, reached US$37.5 billion for 2QFY26, up 66% year-over-year, with a significant portion allocated to short-lived assets like GPUs and CPUs [7]. - Management anticipates a decrease in capital expenditures in 3QFY26 due to normal variability in cloud infrastructure buildouts [7]. Earnings Summary - For FY26E, revenue is projected at US$327.7 billion, with a year-over-year growth of 16.3% [8]. - Net profit is expected to reach US$129.5 billion, reflecting a 27.1% year-over-year increase [8]. - The earnings per share (EPS) for FY26E is estimated at US$17.41, with a P/E ratio of 27.7x [8]. Share Performance and Market Data - The current market capitalization of Microsoft is approximately US$3.59 trillion, with an average turnover of US$12.08 billion over the last three months [3]. - The stock has a 52-week high of US$542.07 and a low of US$354.56 [3].

Report Summary 1. Report Industry Investment Rating - Not provided in the given content. 2. Core Viewpoints - China's economic rebalancing and global liquidity easing are expected to support stocks, commodities, and EM currencies in 1H26, but may face challenges in 2H26 if US inflation resurges [3][11][17]. - The convergence of China's economic rebalancing and global liquidity easing is likely to bolster risky assets throughout 1H26, while the outlook for 2H26 is more cautious [17]. 3. Summary by Relevant Catalogs Trading Desk Comments - In the Chinese IG space, MEITUA and KUAISH had balanced two - way flows, with slightly better selling on 10yr issues; ZHOSHK tightened 1bp; ORIEAS/CCAMCL papers with <5yr tenor tightened 1 - 3bps [2]. - In HK, FRESHK curve tightened 3 - 5bps; BNKEA T2s traded mixed; NWDEVL/VDNWDL complex surged 0.7 - 7.3pts; LASUDE 26 rose 0.9pt; FAEACO 12.814 Perp was 0.5pt higher; EHICAR 26 dropped 1.4pts [2]. - In Chinese properties, VNKRLE 27 - 29 rose 1.5 - 1.8pts; SHUION 29/DALWAN 28 gained 0.4pt; DALWAN priced USD360mn new bond; LNGFOR 27 - 32/FUTLAN 28/FTLNHD 26 - 27 rose 0.3 - 1.2pts [2]. - In KR space, HYUELE 29s tightened 4bps; AU and JP fixed - rate IG credits squeezed 1 - 2bps tighter; JP bank FRNs tightened 1 - 2bps; JP insurance subs remained better offered; there were decent two - way flows in Yankee AT1s [2]. - In SE Asian space, BBLTB T2s tightened 2 - 3bps; GLPSP Perps rose 1.1 - 1.3pts; VEDLN 28 - 33s were unchanged to 0.4pt higher; INDYIJ 29 lost 0.4pt; MEDCIJ 26 - 30s were unchanged to 0.2pt lower [2]. - In the Middle Eastern space, long - end KSAs lost 0.1 - 0.3pt; SNBAB 6.15 Perp was 0.1pt lower; SECO 36 tightened 1bp; ARAMCO attracted better buying but closed largely unchanged [2]. Macro News Recap - On Thursday, S&P (-0.13%), Dow (+0.11%), and Nasdaq (-0.72%) were mixed; US latest initial jobless claims were +209k, higher than the market expectation; UST yield was lower, with 2/5/10/30 - year yield at 3.53%/3.80%/4.24%/4.85% [6]. Desk Analyst Comments - Regarding NWDEVL/VDNWDL, media reported Blackstone in advanced discussions to become NWD's largest shareholder; NWD confirmed potential investors approached, but no agreement reached; Cheng's family owns c45% of NWD [7]. - Cheng's family reshuffled group entities: transferred c54% of CTF Jewellery to Beyond Luck Limited; increased stakes in CTFH by 9.49% to 90.52%; CTFE to sell Alinta Energy to Sembcorp for AUD6.5bn (cUSD4.3bn) [8]. - Maintain buy on VDNWDL 9 Perp due to higher certainty of coupon payments; expect more corporate actions for NWDEVLs [9]. China Policy: Signals for Economic Rebalancing - China's policymakers signaled a pivot to "boosting domestic demand" in 2026 to address economic imbalance [10]. - Demand - side policies focus on stabilizing the property market and stimulating consumption; supply - side policies aim to address overcapacity; trade - side policies employ a four - pronged approach [10]. - The rebalancing process may lead to a GDP growth target reduction to 4.5% - 5% in 2026, but is structurally positive [10]. Offshore Asia New Issues - Issued: Dalian Wanda issued USD360mn 2 - yr bond at 12.75% coupon; First Abu Dhabi Bank PJS issued USD750mn 5 - yr bond at SOFR+75; Muthoot Finance issued USD600mn 4.5 - yr bond at 5.75% coupon [19][20]. - Pipeline: No offshore Asia new issues pipeline on this day [20]. News and Market Color - 101 credit bonds were issued yesterday in onshore primary issuances, amounting to RMB82bn; month - to - date, 1,920 credit bonds were issued with RMB1,652bn raised, a 13.5% yoy increase [25]. - Adani Group plans to raise up to cUSD1.5bn in JPY - denominated bonds and loans [25]. - China Overseas Grand Oceans and Yuexiu Property propose to issue 3 - yr dim sum bonds [25]. - China Vanke to make partial payment for 21Wanke02 onshore bonds on 30 Jan'26 [25]. - West China Cement's proposed acquisition of AfriSam Holdings has a consideration of USD150mn [25].

Investment Rating - The report maintains a "BUY" rating for Sunny Optical, with a new target price (TP) of HK$91.38, implying a potential upside of 45.3% from the current price of HK$62.90 [3][14]. Core Insights - Sunny Optical has announced a positive profit alert for FY25E, projecting a net profit growth of 70-75% year-over-year, driven by high-end specification upgrades, improved product mix, and investment income from a deal with Goertek Optical Tech [1][9]. - For FY26, the company expects revenue growth to be supported by trends in smart driving, AI/AR glasses, and high-end camera specifications, which will help offset weaknesses in the smartphone segment due to memory cost pressures [1][9]. - The report indicates a slight reduction in FY26-27E EPS estimates by 1-4% to account for headwinds in the smartphone industry [1][9]. Financial Summary - Revenue projections for FY25E are set at RMB 42,056 million, with a year-over-year growth of 9.8%. For FY26E, revenue is expected to decline slightly to RMB 41,582 million, followed by a recovery to RMB 45,468 million in FY27E [2][22]. - Net profit is forecasted to reach RMB 4,610 million in FY25E, a 70.8% increase year-over-year, but is expected to decrease to RMB 3,909 million in FY26E before rebounding to RMB 4,699 million in FY27E [2][22]. - The report highlights a projected EPS of RMB 4.24 for FY25E, with consensus estimates at RMB 3.25 for the same period [2][11]. Valuation - The new target price of HK$91.38 is derived from a sum-of-the-parts (SOTP) valuation methodology, applying a target P/E multiple of 23.4x FY26E EPS, reflecting the company's diversified business model and growth potential across various segments [3][14][16]. - The report assigns different P/E multiples to various business segments, with 23x for camera modules and handset lenses, and 25x for vehicle lenses, reflecting their respective market positions and growth prospects [15][16].

Macro Commentary - Chinese policymakers are signaling a strategic shift to prioritize domestic demand as the primary economic task by 2026, addressing issues like overcapacity, deflationary pressures, and weak confidence [2] - Demand-side policies will focus on stabilizing the real estate market and boosting consumption through measures such as lowering mortgage rates and purchasing unsold properties [2] - Supply-side policies will aim at structural adjustments, enhancing industry concentration by curbing capacity expansion and encouraging mergers and acquisitions [6] Market Performance - The Hang Seng Index closed at 27,968, up 0.51% for the day and 9.12% year-to-date, while the Hang Seng Tech Index fell by 1.00% [3] - The Chinese stock market saw gains, particularly in real estate, consumer staples, and financial sectors, with net inflows of 4.374 billion HKD from southbound funds [5] - The U.S. stock market experienced a pullback, with technology, consumer discretionary, and materials sectors leading the decline, while communication services, real estate, and energy sectors gained [5] Company Insights - Meta (META US) reported a 24% year-on-year revenue increase to 59.9 billion USD for Q4 2025, driven by AI-enhanced advertising growth, and provided a revenue guidance of 53.5-56.5 billion USD for Q1 2026 [6] - Microsoft (MSFT US) achieved 16.7% revenue growth to 81.3 billion USD in Q2 FY26, with strong performance in productivity and business processes, and provided a target price of 614.6 USD [6] - ServiceNow (NOW US) reported a 21% revenue increase to 3.57 billion USD for Q4 2025, with a positive outlook for FY26 driven by AI efficiencies, maintaining a target price of 215.0 USD [7][8] - Sunny Optical Technology (2382 HK) expects a 70-75% increase in net profit for 2025, driven by high-end camera upgrades and growth in automotive and smart glasses segments, with a target price of 91.38 HKD [8]

Market Performance - The Hang Seng Index closed at 27,827, up 2.58% for the day and 8.57% year-to-date [1] - The Hang Seng Tech Index rose by 2.53%, with a year-to-date increase of 6.96% [1] - The Shanghai Composite Index saw a modest increase of 0.27%, with a year-to-date rise of 4.60% [1] - The US markets showed mixed results, with the Dow Jones up 0.02% and the S&P 500 down 0.01% [1] Sector Performance - In the Hong Kong market, the Hang Seng Financial Index increased by 2.62%, while the Hang Seng Real Estate Index rose by 3.03%, reflecting strong performance in these sectors [2] - The Chinese stock market saw gains in materials, energy, and telecommunications, while consumer staples, utilities, and healthcare lagged [3] Company Insights - New Oriental (EDU US) reported a 15% year-on-year revenue growth to $1.19 billion, exceeding Bloomberg consensus estimates by 3% [5] - The company’s non-GAAP operating profit surged by 207% to $89.13 million, driven by improved operational efficiency and utilization in its education business [5] - New Oriental raised its revenue guidance for FY26E to a range of $5.29 billion to $5.49 billion, indicating a year-on-year growth of 8%-12% [5] Economic Indicators - The USD/CNY exchange rate fluctuated around 6.94, indicating stability in the currency market [3] - The US Federal Reserve maintained interest rates, with indications of a hawkish stance in future meetings, suggesting economic activity is expanding steadily [3][4]

Investment Rating - The report maintains a "BUY" rating on New Oriental, indicating a strong core educational business, solid margin expansion trend, and attractive shareholder return [1][18]. Core Insights - New Oriental's 2QFY26 results exceeded expectations, with net revenue increasing by 15% YoY to US$1.19 billion, surpassing Bloomberg consensus estimates by 3% [1]. - Non-GAAP operating income surged by 207% YoY to US$89.13 million, significantly beating the consensus estimate of US$54.87 million, driven by enhanced operational efficiency [1]. - The management anticipates net revenue growth of 11-14% YoY for 3QFY26E, raising the FY26E net revenue forecast to US$5.29-5.49 billion, reflecting solid momentum in new educational and high-school tutoring businesses [1]. Financial Performance - Revenue projections for FY26E are set at US$5.47 billion, with a YoY growth of 11.6%, and adjusted net profit is expected to reach US$594.2 million [2]. - The report forecasts a continued revenue growth trajectory, with FY27E and FY28E revenues projected at US$5.99 billion and US$6.46 billion, respectively [2]. - Non-GAAP operating profit margin (OPM) is expected to expand to 12.8% in 3QFY26E, up from 7.5% in 2QFY26, indicating improved operational efficiency [9][10]. Valuation - The target price for New Oriental is set at US$78.00, reflecting a 32.3% upside from the current price of US$58.95 [3]. - The valuation is derived from a sum-of-the-parts (SOTP) analysis, with the educational and consulting business valued at US$75.00 based on a 25x FY26E PE ratio [12][13]. - The report highlights a strong growth outlook for the educational segment, with a revenue CAGR of 10% expected from FY26 to FY28 [13].

Group 1: Market Overview - The Hang Seng Index closed at 27,127, up 1.35% for the day and 5.84% year-to-date [1] - The Hang Seng Financial Index rose by 2.51% for the day and 5.88% year-to-date, indicating strong performance in the financial sector [2] - Southbound capital recorded a net sell of 635 million HKD, with notable sell-offs in China Mobile, Zijin Mining, and SMIC, while Tencent and Longi Green Energy saw significant net buying [3] Group 2: Company Analysis - Sanofi - Sanofi's collaboration with Pfizer on the 707/PF'4404 (PD-1/VEGF) has advanced rapidly, with plans to initiate four global Phase III clinical trials by 2026 covering five major indications [4] - The dual antibody PD-(L)1/VEGF is expected to become a cornerstone in next-generation tumor immunotherapy, with Sanofi leveraging its internal pipeline for competitive advantage [5] - Sanofi's robust pipeline includes multiple candidates, with the potential for early assets to be licensed out as clinical data matures [6] Group 3: Financial Projections - The target price for Sanofi is set at 37.43 HKD, based on a DCF model with a WACC of 10.11% and a perpetual growth rate of 2.0% [7] - The company is estimated to have net cash of approximately 13 billion HKD, supporting its growth and development initiatives [7]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four Phase III trials in 2026 targeting five major indications. This development is expected to position Pfizer favorably in the competitive landscape of next-generation cancer immunotherapy [1][8]. - The collaboration between Pfizer and the company is anticipated to unlock significant global value for 707/PF'4404, serving as a key catalyst for the company's upward trajectory [1][8]. - The company is also increasing its R&D investments, with multiple pipelines expected to yield clinical data soon, enhancing the potential for external licensing opportunities [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. Projections for FY24A and FY25E are RMB 9,108 million and RMB 17,972 million, respectively, indicating a significant growth trajectory [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, reflecting a decline of 19.1% year-on-year, but is expected to rebound to RMB 2,090 million in FY24A and surge to RMB 9,741 million in FY25E, marking a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY25E is projected at RMB 3.84, with a price-to-earnings (P/E) ratio of 5.6, indicating a strong valuation relative to earnings [2][15]. Market Position and Shareholder Structure - The company's market capitalization stands at HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6%, indicating a concentrated ownership structure [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs (antibody-drug conjugates) as a unique advantage [1][8]. - The company has several promising candidates in its pipeline, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1), which are currently in Phase II trials in China [8][12]. Valuation and Forecast Adjustments - The report adjusts the financial forecasts for FY25E and FY26E, reflecting a slight increase in revenue expectations due to the anticipated success of the 707 program [12][13]. - The DCF valuation analysis estimates a per-share value of HKD 37.43, based on a weighted average cost of capital (WACC) of 10.11% and a perpetual growth rate of 2.0% [13][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four global Phase III trials in 2026 targeting five major indications. The combination of PD-(L)1/VEGF dual antibodies is expected to become a cornerstone of next-generation cancer immunotherapy, positioning Pfizer to leverage its internal pipeline synergy and strong clinical execution capabilities [1][8]. - The company is increasing its R&D investments, with several pipelines expected to yield clinical data soon. The core business fundamentals remain robust, providing a safety margin, and the company is projected to achieve significant revenue growth driven by its innovative pipeline [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. The projected sales revenue for FY25E is RMB 17,972 million, reflecting a substantial increase of 97.3% [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, with a year-on-year decline of 19.1%. However, the forecast for FY25E shows a significant increase to RMB 9,741 million, indicating a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY23A was RMB 0.64, expected to rise to RMB 3.84 in FY25E [2][15]. Market Position and Shareholder Structure - The company's market capitalization is approximately HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6% [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs as a unique advantage. The company plans to conduct multiple Phase III trials for various indications, including NSCLC and mCRC, with a focus on rapid patient recruitment [1][8]. - The ongoing clinical trials for other innovative products, such as 705 (PD-1/HER2) and 706 (PD-1/PD-L1), are also expected to contribute to the company's growth and potential licensing opportunities [8][12].

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,766, up 0.06% for the day and up 4.43% year-to-date [1] - The US markets saw gains, with the Dow Jones up 0.64% and the S&P 500 up 0.50%, while the Nasdaq increased by 0.43% [1] - The Chinese stock market exhibited mixed results, with A-shares declining, particularly in defense, automotive, and social services sectors, while non-ferrous metals, oil, and coal sectors showed gains [3] Sector Performance - In the Hong Kong market, the Hang Seng Financial Index rose by 0.74%, while the Hang Seng Real Estate Index increased by 1.84%, indicating strong performance in these sectors [2] - Conversely, the Hang Seng Industrial Index fell by 0.44%, reflecting weaker performance in industrial stocks [2] Company Analysis - China Resources Beverage (2460 HK) is projected to see a 35.5% decline in net profit for FY2025, estimated at RMB 1.06 billion, primarily due to increased marketing expenditures and slower capacity expansion [4] - Despite the anticipated profit drop, there are positive indicators such as a new experienced chairman likely to drive significant reforms, and potential increases in dividend payouts [4] - The report maintains a "Buy" rating for China Resources Beverage, with a target price adjusted down by 8% to HKD 11.87, reflecting the earnings downgrade [4]